NCT05337319 Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease
| NCT ID | NCT05337319 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Anzhen Hospital |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2022-01-17 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2022-01-17 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will estimate the current status of care for participants with coronary artery disease
Eligibility Criteria
Inclusion Criteria: * Hospitalized patients with discharge diagnosis as coronary artery disease (including atherosclerosis or non-athrosclerosis) Exclusion Criteria: * None
Contact & Investigator
Shaoping Nie, MD, PhD
PRINCIPAL INVESTIGATOR
Beijing Anzhen Hospital
Frequently Asked Questions
Who can join the NCT05337319 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05337319 currently recruiting?
Yes, NCT05337319 is actively recruiting participants. Contact the research team at spnie@ccmu.edu.cn for enrollment information.
Where is the NCT05337319 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05337319 clinical trial?
NCT05337319 is sponsored by Beijing Anzhen Hospital. The principal investigator is Shaoping Nie, MD, PhD at Beijing Anzhen Hospital. The trial plans to enroll 100,000 participants.